What is Raymond James's price target for AMED?

Raymond James's latest stated price target for Amedisys Inc (AMED) is $200, from its action on Feb 25, 2022.

What is Raymond James's rating on AMED?

Raymond James rates AMED Mkt Perform, a neutral rating, as of Oct 27, 2022.

When did Raymond James last change its view on AMED?

On Oct 27, 2022, Raymond James downgrades to Mkt Perform from Outperform.

Raymond James AMED price target and rating history

Raymond James rates Amedisys Inc (AMED) Mkt Perform with a $200 price target, as of its latest action on Oct 27, 2022. It has published 4 rating actions on AMED since August 2021, including 0 upgrades and 1 downgrade.

Current rating: Mkt Perform
Price target: $200
Median target, all firms: Too few
Actions on AMED: 4

Raymond James price target on AMED

Raymond James price target on AMED, each point a stated target, August 2021 to February 2022.

Every Raymond James rating on AMED

Oct 27, 2022
DowngradeRaymond James downgrades to Mkt Perform from Outperform
Feb 25, 2022
ReiterateRaymond James cuts its price target to $200 from $225, keeps Outperform
Nov 8, 2021
ReiterateRaymond James cuts its price target to $225 from $250, keeps Outperform
Aug 10, 2021
ReiterateRaymond James cuts its price target to $250 from $325, keeps Outperform

Questions about Raymond James and AMED

What is Raymond James's price target for AMED?: Raymond James's latest stated price target for Amedisys Inc (AMED) is $200, from its action on Feb 25, 2022.
What is Raymond James's rating on AMED?: Raymond James rates AMED Mkt Perform, a neutral rating, as of Oct 27, 2022.
When did Raymond James last change its view on AMED?: On Oct 27, 2022, Raymond James downgrades to Mkt Perform from Outperform.

More AMED rating histories

All Raymond James ratings AMED news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.